tirzepatide for heart failure 💊 New research in obesity & The SUMMIT study looked at tirzepatide, a once-weekly injection, in people with both obesity and heart failure with preserved ejection fraction (HFpEF). Over 52 SUMMIT: Tirzepatide a 'Huge Win'

Methods This observational pre-post study used Optums de-identified Market Clarity Data from January 1, 2007, to June 30, 2024

It is effective

While branded semaglutide without insurance can be pricey, coverage with assistance from Klinic's prior authorization greatly reduces costs for many clients

In addition to demonstrating the noninferiority of insulin glargine U-300 to insulin degludec U-100 with respect to its primary and main secondary endpoints, InRange was the first large randomized controlled trial to use CGM-based TIR as a primary efficacy endpoint, which may herald a shift toward incorporating CGM-based metrics into clinical trials